Cargando…

The convergent application of metabolites from Avena sativa and gut microbiota to ameliorate non-alcoholic fatty liver disease: a network pharmacology study

BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is a serious public health issue globally, currently, the treatment of NAFLD lies still in the labyrinth. In the inchoate stage, the combinatorial application of food regimen and favorable gut microbiota (GM) are considered as an alternative ther...

Descripción completa

Detalles Bibliográficos
Autores principales: Oh, Ki-Kwang, Yoon, Sang-Jun, Lee, Su-Been, Lee, Sang Youn, Gupta, Haripriya, Ganesan, Raja, Sharma, Satya Priya, Won, Sung-Min, Jeong, Jin-Ju, Kim, Dong Joon, Suk, Ki-Tae
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10111676/
https://www.ncbi.nlm.nih.gov/pubmed/37069607
http://dx.doi.org/10.1186/s12967-023-04122-6
_version_ 1785027494994247680
author Oh, Ki-Kwang
Yoon, Sang-Jun
Lee, Su-Been
Lee, Sang Youn
Gupta, Haripriya
Ganesan, Raja
Sharma, Satya Priya
Won, Sung-Min
Jeong, Jin-Ju
Kim, Dong Joon
Suk, Ki-Tae
author_facet Oh, Ki-Kwang
Yoon, Sang-Jun
Lee, Su-Been
Lee, Sang Youn
Gupta, Haripriya
Ganesan, Raja
Sharma, Satya Priya
Won, Sung-Min
Jeong, Jin-Ju
Kim, Dong Joon
Suk, Ki-Tae
author_sort Oh, Ki-Kwang
collection PubMed
description BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is a serious public health issue globally, currently, the treatment of NAFLD lies still in the labyrinth. In the inchoate stage, the combinatorial application of food regimen and favorable gut microbiota (GM) are considered as an alternative therapeutic. Accordingly, we integrated secondary metabolites (SMs) from GM and Avena sativa (AS) known as potent dietary grain to identify the combinatorial efficacy through network pharmacology. METHODS: We browsed the SMs of AS via Natural Product Activity & Species Source (NPASS) database and SMs of GM were retrieved by gutMGene database. Then, specific intersecting targets were identified from targets related to SMs of AS and GM. The final targets were selected on NAFLD-related targets, which was considered as crucial targets. The protein–protein interaction (PPI) networks and bubble chart analysis to identify a hub target and a key signaling pathway were conducted, respectively. In parallel, we analyzed the relationship of GM or AS─a key signaling pathway─targets─SMs (GASTM) by merging the five components via RPackage. We identified key SMs on a key signaling pathway via molecular docking assay (MDA). Finally, the identified key SMs were verified the physicochemical properties and toxicity in silico platform. RESULTS: The final 16 targets were regarded as critical proteins against NAFLD, and Vascular Endothelial Growth Factor A (VEGFA) was a key target in PPI network analysis. The PI3K-Akt signaling pathway was the uppermost mechanism associated with VEGFA as an antagonistic mode. GASTM networks represented 122 nodes (60 GM, AS, PI3K-Akt signaling pathway, 4 targets, and 56 SMs) and 154 edges. The VEGFA-myricetin, or quercetin, GSK3B-myricetin, IL2-diosgenin complexes formed the most stable conformation, the three ligands were derived from GM. Conversely, NR4A1-vestitol formed stable conformation with the highest affinity, and the vestitol was obtained from AS. The given four SMs were no hurdles to develop into drugs devoid of its toxicity. CONCLUSION: In conclusion, we show that combinatorial application of AS and GM might be exerted to the potent synergistic effects against NAFLD, dampening PI3K-Akt signaling pathway. This work provides the importance of dietary strategy and beneficial GM on NAFLD, a data mining basis for further explicating the SMs and pharmacological mechanisms of combinatorial application (AS and GM) against NAFLD. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12967-023-04122-6.
format Online
Article
Text
id pubmed-10111676
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-101116762023-04-19 The convergent application of metabolites from Avena sativa and gut microbiota to ameliorate non-alcoholic fatty liver disease: a network pharmacology study Oh, Ki-Kwang Yoon, Sang-Jun Lee, Su-Been Lee, Sang Youn Gupta, Haripriya Ganesan, Raja Sharma, Satya Priya Won, Sung-Min Jeong, Jin-Ju Kim, Dong Joon Suk, Ki-Tae J Transl Med Research BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is a serious public health issue globally, currently, the treatment of NAFLD lies still in the labyrinth. In the inchoate stage, the combinatorial application of food regimen and favorable gut microbiota (GM) are considered as an alternative therapeutic. Accordingly, we integrated secondary metabolites (SMs) from GM and Avena sativa (AS) known as potent dietary grain to identify the combinatorial efficacy through network pharmacology. METHODS: We browsed the SMs of AS via Natural Product Activity & Species Source (NPASS) database and SMs of GM were retrieved by gutMGene database. Then, specific intersecting targets were identified from targets related to SMs of AS and GM. The final targets were selected on NAFLD-related targets, which was considered as crucial targets. The protein–protein interaction (PPI) networks and bubble chart analysis to identify a hub target and a key signaling pathway were conducted, respectively. In parallel, we analyzed the relationship of GM or AS─a key signaling pathway─targets─SMs (GASTM) by merging the five components via RPackage. We identified key SMs on a key signaling pathway via molecular docking assay (MDA). Finally, the identified key SMs were verified the physicochemical properties and toxicity in silico platform. RESULTS: The final 16 targets were regarded as critical proteins against NAFLD, and Vascular Endothelial Growth Factor A (VEGFA) was a key target in PPI network analysis. The PI3K-Akt signaling pathway was the uppermost mechanism associated with VEGFA as an antagonistic mode. GASTM networks represented 122 nodes (60 GM, AS, PI3K-Akt signaling pathway, 4 targets, and 56 SMs) and 154 edges. The VEGFA-myricetin, or quercetin, GSK3B-myricetin, IL2-diosgenin complexes formed the most stable conformation, the three ligands were derived from GM. Conversely, NR4A1-vestitol formed stable conformation with the highest affinity, and the vestitol was obtained from AS. The given four SMs were no hurdles to develop into drugs devoid of its toxicity. CONCLUSION: In conclusion, we show that combinatorial application of AS and GM might be exerted to the potent synergistic effects against NAFLD, dampening PI3K-Akt signaling pathway. This work provides the importance of dietary strategy and beneficial GM on NAFLD, a data mining basis for further explicating the SMs and pharmacological mechanisms of combinatorial application (AS and GM) against NAFLD. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12967-023-04122-6. BioMed Central 2023-04-17 /pmc/articles/PMC10111676/ /pubmed/37069607 http://dx.doi.org/10.1186/s12967-023-04122-6 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Oh, Ki-Kwang
Yoon, Sang-Jun
Lee, Su-Been
Lee, Sang Youn
Gupta, Haripriya
Ganesan, Raja
Sharma, Satya Priya
Won, Sung-Min
Jeong, Jin-Ju
Kim, Dong Joon
Suk, Ki-Tae
The convergent application of metabolites from Avena sativa and gut microbiota to ameliorate non-alcoholic fatty liver disease: a network pharmacology study
title The convergent application of metabolites from Avena sativa and gut microbiota to ameliorate non-alcoholic fatty liver disease: a network pharmacology study
title_full The convergent application of metabolites from Avena sativa and gut microbiota to ameliorate non-alcoholic fatty liver disease: a network pharmacology study
title_fullStr The convergent application of metabolites from Avena sativa and gut microbiota to ameliorate non-alcoholic fatty liver disease: a network pharmacology study
title_full_unstemmed The convergent application of metabolites from Avena sativa and gut microbiota to ameliorate non-alcoholic fatty liver disease: a network pharmacology study
title_short The convergent application of metabolites from Avena sativa and gut microbiota to ameliorate non-alcoholic fatty liver disease: a network pharmacology study
title_sort convergent application of metabolites from avena sativa and gut microbiota to ameliorate non-alcoholic fatty liver disease: a network pharmacology study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10111676/
https://www.ncbi.nlm.nih.gov/pubmed/37069607
http://dx.doi.org/10.1186/s12967-023-04122-6
work_keys_str_mv AT ohkikwang theconvergentapplicationofmetabolitesfromavenasativaandgutmicrobiotatoamelioratenonalcoholicfattyliverdiseaseanetworkpharmacologystudy
AT yoonsangjun theconvergentapplicationofmetabolitesfromavenasativaandgutmicrobiotatoamelioratenonalcoholicfattyliverdiseaseanetworkpharmacologystudy
AT leesubeen theconvergentapplicationofmetabolitesfromavenasativaandgutmicrobiotatoamelioratenonalcoholicfattyliverdiseaseanetworkpharmacologystudy
AT leesangyoun theconvergentapplicationofmetabolitesfromavenasativaandgutmicrobiotatoamelioratenonalcoholicfattyliverdiseaseanetworkpharmacologystudy
AT guptaharipriya theconvergentapplicationofmetabolitesfromavenasativaandgutmicrobiotatoamelioratenonalcoholicfattyliverdiseaseanetworkpharmacologystudy
AT ganesanraja theconvergentapplicationofmetabolitesfromavenasativaandgutmicrobiotatoamelioratenonalcoholicfattyliverdiseaseanetworkpharmacologystudy
AT sharmasatyapriya theconvergentapplicationofmetabolitesfromavenasativaandgutmicrobiotatoamelioratenonalcoholicfattyliverdiseaseanetworkpharmacologystudy
AT wonsungmin theconvergentapplicationofmetabolitesfromavenasativaandgutmicrobiotatoamelioratenonalcoholicfattyliverdiseaseanetworkpharmacologystudy
AT jeongjinju theconvergentapplicationofmetabolitesfromavenasativaandgutmicrobiotatoamelioratenonalcoholicfattyliverdiseaseanetworkpharmacologystudy
AT kimdongjoon theconvergentapplicationofmetabolitesfromavenasativaandgutmicrobiotatoamelioratenonalcoholicfattyliverdiseaseanetworkpharmacologystudy
AT sukkitae theconvergentapplicationofmetabolitesfromavenasativaandgutmicrobiotatoamelioratenonalcoholicfattyliverdiseaseanetworkpharmacologystudy
AT ohkikwang convergentapplicationofmetabolitesfromavenasativaandgutmicrobiotatoamelioratenonalcoholicfattyliverdiseaseanetworkpharmacologystudy
AT yoonsangjun convergentapplicationofmetabolitesfromavenasativaandgutmicrobiotatoamelioratenonalcoholicfattyliverdiseaseanetworkpharmacologystudy
AT leesubeen convergentapplicationofmetabolitesfromavenasativaandgutmicrobiotatoamelioratenonalcoholicfattyliverdiseaseanetworkpharmacologystudy
AT leesangyoun convergentapplicationofmetabolitesfromavenasativaandgutmicrobiotatoamelioratenonalcoholicfattyliverdiseaseanetworkpharmacologystudy
AT guptaharipriya convergentapplicationofmetabolitesfromavenasativaandgutmicrobiotatoamelioratenonalcoholicfattyliverdiseaseanetworkpharmacologystudy
AT ganesanraja convergentapplicationofmetabolitesfromavenasativaandgutmicrobiotatoamelioratenonalcoholicfattyliverdiseaseanetworkpharmacologystudy
AT sharmasatyapriya convergentapplicationofmetabolitesfromavenasativaandgutmicrobiotatoamelioratenonalcoholicfattyliverdiseaseanetworkpharmacologystudy
AT wonsungmin convergentapplicationofmetabolitesfromavenasativaandgutmicrobiotatoamelioratenonalcoholicfattyliverdiseaseanetworkpharmacologystudy
AT jeongjinju convergentapplicationofmetabolitesfromavenasativaandgutmicrobiotatoamelioratenonalcoholicfattyliverdiseaseanetworkpharmacologystudy
AT kimdongjoon convergentapplicationofmetabolitesfromavenasativaandgutmicrobiotatoamelioratenonalcoholicfattyliverdiseaseanetworkpharmacologystudy
AT sukkitae convergentapplicationofmetabolitesfromavenasativaandgutmicrobiotatoamelioratenonalcoholicfattyliverdiseaseanetworkpharmacologystudy